EUVIMEDEUVIMED entdecken
Crossref

Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy

Igryl S Cordero-Hernandez, Alicia C Ross, Arvind Dasari iD, Daniel M Halperin iD, Beth Chasen, James C Yao iD

Endocrine-Related Cancer · 2024

DOI: 10.1530/erc-23-0203 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2024. Verfasst von Igryl S Cordero-Hernandez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Carcinoma, Neuroendocrine, Lutetium, Radioisotopes. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We observed that some patients with well-differentiated neuroendocrine tumors (NET) who received peptide receptor radionuclide therapy (PRRT) with Lutetium-177 ( 177 Lu) DOTATATE developed rapid disease progression with biopsy-proven histologic transformation to neuroendocrine carcinoma (NEC), an outcome that has not been previously described. Therefore, we conducted a retrospective review of all patients with well-differentiated G1-G2 NET who received at least one cycle of PRRT with ( 177 Lu) DOTATATE at our center from January 2019 to December 2020. Among 152 patients, we identified 7 patients whose NET transformed to NEC. Median time from start of PRRT to transformation was 8.2 months (range: 2.6–14.4 months). All patients whose tumors underwent transformation had pancreatic tail as the primary site and had prior chemotherapy with temozolomide. No differences in the incidence of transformation were observed according to gender, race, original tumor grade, or number of prior therapies. Six patients received treatment with platinum and etoposide after transformation with two patients having partial response as best response. All patients with transformation died from progressive disease with median overall survival (OS) after transformation of 3.3 months (95% CI 2.1–4.4). Molecular testing of transformed NEC identified mutation(s) in TP53 and/or ATM in all cases. Transformation of NET to NEC following PRRT is associated with aggressive course and dismal prognosis. Patients with pancreatic tail as the primary site who had prior therapy with temozolomide may be at a higher risk. Further investigation is necessary to determine the best treatment sequence in this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsCarcinoma, NeuroendocrineLutetiumRadioisotopesHumansTemozolomideBiopsyReceptors, Peptide

Stichwörter der Autor:innen

neuroendocrine carcinomaneuroendocrine tumorpeptide receptor radionuclide therapy (PRRT)poorly differentiated transformation

Substanzen

TemozolomideLutetium-177Receptors, PeptideLutetiumRadioisotopes

Autor:innen und Institutionen

  • Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Arvind Dasari, Daniel M Halperin, James C Yao

Zitieren

APA

Cordero-Hernandez, I. S., Ross, A. C., Dasari, A., Halperin, D. M., Chasen, B., & Yao, J. C. (2024). Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy. Endocrine-Related Cancer. https://doi.org/10.1530/erc-23-0203

Vancouver

Cordero-Hernandez IS, Ross AC, Dasari A, Halperin DM, Chasen B, Yao JC. Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy. Endocrine-Related Cancer. 2024. doi:10.1530/erc-23-0203

BibTeX
@article{CorderoHernandez2024,
  author = {Cordero-Hernandez, Igryl S and Ross, Alicia C and Dasari, Arvind and Halperin, Daniel M and Chasen, Beth and Yao, James C},
  title = {Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy},
  journal = {Endocrine-Related Cancer},
  year = {2024},
  doi = {10.1530/erc-23-0203}
}
Kostenlos starten →